{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:50:01Z","timestamp":1792043401873,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["VR 2022- 01098"],"award-info":[{"award-number":["VR 2022- 01098"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["23 2921"],"award-info":[{"award-number":["23 2921"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821528"],"award-info":[{"award-number":["821528"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serum neurofilament light chain (sNfL), a biomarker of axonal damage, has shown promise in clinical studies for monitoring paclitaxel-induced peripheral neurotoxicity (PIPN). The latter involves pathological changes in PIPN sites such as the dorsal root ganglia, peripheral nerves, and brain. However, the mechanistic link between paclitaxel and NfL concentrations in these tissues remains poorly understood, necessitating preclinical investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a semi-mechanistic pharmacokinetic-pharmacodynamic model to characterize: (i) total and unbound paclitaxel concentrations in plasma, as well as in extracellular and intracellular compartments of PIPN sites; (ii) paclitaxel\u2013tubulin complex formation; and (iii) NfL kinetics. The model was built using de novo-generated and previously reported data from rodents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Plasma pharmacokinetics of paclitaxel was captured using a two-compartment model, including Cremophor EL trapping and nonlinear tissue distribution. Paclitaxel pharmacokinetics in PIPN sites incorporated paclitaxel transport across the blood-to-PIPN sites barriers and paclitaxel\u2013tubulin binding, described by capacity-limited kinetics with increased tubulin binding upon repeated plasma exposure. NfL kinetics in serum and cerebrospinal fluid were described using turnover models, with NfL leakage driven by paclitaxel\u2013tubulin complex formation in PIPN sites. The model robustly predicted paclitaxel exposure across multiple doses and studies. While NfL predictions aligned with single-dose data, the model slightly underpredicted sNfL levels in an external validation dataset after repeated dosing of paclitaxel at 15\u00a0mg\/kg, suggesting additional mechanisms may be involved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, the model successfully described the relationship between paclitaxel exposure and sNfL kinetics, offering a model-based framework for translational studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11095-026-04053-z","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:58:26Z","timestamp":1773421106000},"page":"1071-1088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of sNfL as a Biomarker for Paclitaxel-Induced Peripheral Neurotoxicity Through an Integrated PKPD Model"],"prefix":"10.1007","volume":"43","author":[{"given":"Eman I. K.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milda","family":"Girdenyt\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Di Cesare Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Balayssac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Busserolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diethilde","family":"Theil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Roussignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Perrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Le Berre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Chanut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Slaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1557-4416","authenticated-orcid":false,"given":"Irena","family":"Loryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena E.","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"4053_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2024.1345811","volume":"17","author":"X Chen","year":"2024","unstructured":"Chen X, Gan Y, Au NPB, Ma CHE. Current understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2024;17: 1345811.","journal-title":"Front Mol Neurosci"},{"issue":"12","key":"4053_CR2","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461\u201370.","journal-title":"Pain"},{"issue":"10","key":"4053_CR3","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31(10):1306\u201319.","journal-title":"Ann Oncol"},{"key":"4053_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.693133","volume":"8","author":"M Omran","year":"2021","unstructured":"Omran M, Belcher EK, Mohile NA, Kesler SR, Janelsins MC, Hohmann AG, et al. Review of the role of the brain in chemotherapy-induced peripheral neuropathy. Front Mol Biosci. 2021;8: 693133.","journal-title":"Front Mol Biosci"},{"issue":"11","key":"4053_CR5","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1158\/0008-5472.CAN-15-2525","volume":"76","author":"KM Wozniak","year":"2016","unstructured":"Wozniak KM, Vornov JJ, Wu Y, Nomoto K, Littlefield BA, DesJardins C, et al. Sustained accumulation of microtubule-binding chemotherapy drugs in the peripheral nervous system: correlations with time course and neurotoxic severity. Cancer Res. 2016;76(11):3332\u20139.","journal-title":"Cancer Res"},{"key":"4053_CR6","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2147\/IJN.S114356","volume":"12","author":"I Nakamura","year":"2017","unstructured":"Nakamura I, Ichimura E, Goda R, Hayashi H, Mashiba H, Nagai D, et al. An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation. Int J Nanomed. 2017;12:1293\u2013304.","journal-title":"Int J Nanomed"},{"issue":"1","key":"4053_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-024-00519-7","volume":"21","author":"Y Hu","year":"2024","unstructured":"Hu Y, Girdenyt\u00e9 M, Roest L, Liukkonen I, Siskou M, B\u00e4llgren F, et al. Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy. Fluids Barriers CNS. 2024;21(1): 13.","journal-title":"Fluids Barriers CNS"},{"key":"4053_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1486686","volume":"15","author":"M Girdenyt\u0117","year":"2024","unstructured":"Girdenyt\u0117 M, Hu Y, Ginosyan A, Hammarlund-Udenaes M, Loryan I. Formulation-dependent differences in paclitaxel distribution to anatomical sites relevant to chemotherapy-induced peripheral neuropathy. Front Pharmacol. 2024;15: 1486686.","journal-title":"Front Pharmacol"},{"issue":"10","key":"4053_CR9","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1021\/acs.molpharmaceut.8b00527","volume":"15","author":"F Li","year":"2018","unstructured":"Li F, Zhang H, He M, Liao J, Chen N, Li Y, et al. Different nanoformulations alter the tissue distribution of paclitaxel, which aligns with reported distinct efficacy and safety profiles. Mol Pharm. 2018;15(10):4505\u201316.","journal-title":"Mol Pharm"},{"issue":"11","key":"4053_CR10","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","volume":"11","author":"A Sparreboom","year":"2005","unstructured":"Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11(11):4136\u201343.","journal-title":"Clin Cancer Res"},{"key":"4053_CR11","doi-asserted-by":"crossref","unstructured":"Balayssac D, Busserolles J, Broto C, Dalbos C, Prival L, Lamoine S et al. Neurofilament light chain in plasma as a sensitive diagnostic biomarker of peripheral neurotoxicity: In Vivo mouse studies with oxaliplatin and paclitaxel-NeuroDeRisk project. Biomedicine & Pharmacotherapy. 2023;167:115535.","DOI":"10.1016\/j.biopha.2023.115535"},{"key":"4053_CR12","doi-asserted-by":"publisher","unstructured":"Micheli L, Balayssac D, Busserolles J, Dalbos C, Prival L, Richard D,\u00a0Quintana M, Di Cesare Mannelli L, Toti A, Ciampi C, Ghelardini C, Vlasakova K, Glaab WE, Hu Y, Loryan I, Perrault O, Slaoui M, Wuersch K, Johnson E, Frieauff W, Penraat K, Brees D, Dubost V, Theil D\u00a0The challenge to identify sensitive safety biomarkers of peripheral neurotoxicity in the rat: a collaborative effort across industry and academia (IMI NeuroDeRisk project). Toxicology. 2024:153998. https:\/\/doi.org\/10.1016\/j.tox.2024.153998","DOI":"10.1016\/j.tox.2024.153998"},{"key":"4053_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/toxics11121004","author":"D Balayssac","year":"2023","unstructured":"Balayssac D, Durif J, Lambert C, Dalbos C, Chapuy E, Etienne M, et al. Exploring serum biomarkers for neuropathic pain in rat models of chemotherapy-induced peripheral neuropathy: a comparative pilot study with oxaliplatin, paclitaxel, bortezomib, and vincristine. Toxics. 2023. https:\/\/doi.org\/10.3390\/toxics11121004.","journal-title":"Toxics"},{"issue":"1","key":"4053_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.expneurol.2006.07.022","volume":"203","author":"CM Peters","year":"2007","unstructured":"Peters CM, Jimenez-Andrade JM, Jonas BM, Sevcik MA, Koewler NJ, Ghilardi JR, et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol. 2007;203(1):42\u201354.","journal-title":"Exp Neurol"},{"issue":"7","key":"4053_CR15","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00204-020-02755-w","volume":"94","author":"C Meregalli","year":"2020","unstructured":"Meregalli C, Fumagalli G, Alberti P, Canta A, Chiorazzi A, Monza L, et al. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of chemotherapy-induced peripheral neurotoxicity. Arch Toxicol. 2020;94(7):2517\u201322.","journal-title":"Arch Toxicol"},{"issue":"20","key":"4053_CR16","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1200\/JCO.2001.19.20.4065","volume":"19","author":"A Henningsson","year":"2001","unstructured":"Henningsson A, Karlsson MO, Vigan\u00f2 L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol. 2001;19(20):4065\u201373.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4053_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0959-8049(03)00126-6","volume":"39","author":"A Henningsson","year":"2003","unstructured":"Henningsson A, Sparreboom A, Sandstr\u00f6m M, Freijs A, Larsson R, Bergh J, et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer. 2003;39(8):1105\u201314.","journal-title":"Eur J Cancer"},{"issue":"10","key":"4053_CR18","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/jcph.304","volume":"54","author":"N Chen","year":"2014","unstructured":"Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol. 2014;54(10):1097\u2013107.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"4053_CR19","first-page":"1220","volume":"27","author":"MO Karlsson","year":"1999","unstructured":"Karlsson MO, Molnar V, Freijs A, Nygren P, Bergh J, Larsson R. Pharmacokinetic models for the saturable distribution of paclitaxel. Eur J Cancer. 1999;27(10):1220\u20133.","journal-title":"Eur J Cancer"},{"key":"4053_CR20","doi-asserted-by":"publisher","first-page":"864910","DOI":"10.3389\/fpain.2022.864910","volume":"3","author":"RL Rodwin","year":"2022","unstructured":"Rodwin RL, Siddiq NZ, Ehrlich BE, Lustberg MB. Biomarkers of chemotherapy-induced peripheral neuropathy: current status and future directions. Front Pain Res. 2022;3:864910.","journal-title":"Front Pain Res"},{"key":"4053_CR21","doi-asserted-by":"crossref","unstructured":"Huehnchen P, Schinke C, Bangemann N, Dordevic AD, Kern J, Maierhof SK, et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI insight. 2022;7(6).","DOI":"10.1172\/jci.insight.154395"},{"key":"4053_CR22","doi-asserted-by":"publisher","unstructured":"Mortensen C, Steffensen KD, Simonsen E, Herskind K, Madsen JS, Olsen DA, et al. Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer. Pain. 2023;164(7):1502\u201311. https:\/\/doi.org\/10.1097\/j.pain.0000000000002840","DOI":"10.1097\/j.pain.0000000000002840"},{"issue":"2","key":"4053_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jns.12493","volume":"27","author":"S Karteri","year":"2022","unstructured":"Karteri S, Bruna J, Argyriou AA, Mariotto S, Velasco R, Alemany M, et al. Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. J Peripher Nerv Syst. 2022;27(2):166\u201374.","journal-title":"J Peripher Nerv Syst"},{"key":"4053_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162499","author":"P Alberti","year":"2022","unstructured":"Alberti P, Semperboni S, Cavaletti G, Scuteri A. Neurons: the interplay between cytoskeleton, ion channels\/transporters and mitochondria. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11162499.","journal-title":"Cells"},{"issue":"10","key":"4053_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577\u201389.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"4053_CR26","first-page":"196","volume":"12","author":"A Paris","year":"2023","unstructured":"Paris A, Bora P, Parolo S, MacCannell D, Monine M, van der Munnik N, et al. A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen. CPT: Pharmcomet Syst Pharmacol. 2023;12(2):196\u2013206.","journal-title":"CPT: Pharmcomet Syst Pharmacol"},{"issue":"4","key":"4053_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/psp4.12770","volume":"11","author":"A Paris","year":"2022","unstructured":"Paris A, Bora P, Parolo S, Monine M, Tong X, Eraly S, et al. An age-dependent mathematical model of neurofilament trafficking in healthy conditions. CPT Pharmacomet Syst Pharmacol. 2022;11(4):447\u201357.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"4053_CR28","doi-asserted-by":"publisher","unstructured":"Machacek M, Garcia-Montoya E, McColgan P, Sanwald-Ducray P, Mazer NA. NfL concentration in CSF is a quantitative marker of the rate of neurodegeneration in aging and Huntington's disease: a semi-mechanistic model-based analysis. 2024;18. https:\/\/doi.org\/10.3389\/fnins.2024.1420198","DOI":"10.3389\/fnins.2024.1420198"},{"key":"4053_CR29","doi-asserted-by":"publisher","first-page":"668606","DOI":"10.3389\/fneur.2021.668606","volume":"12","author":"S Azizi","year":"2021","unstructured":"Azizi S, Hier DB, Allen B, Obafemi-Ajayi T, Olbricht GR, Thimgan MS, et al. A kinetic model for blood biomarker levels after mild traumatic brain injury. Front Neurol. 2021;12:668606.","journal-title":"Front Neurol"},{"key":"4053_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16369","author":"R Velasco","year":"2024","unstructured":"Velasco R, Marco C, Domingo-Domenech E, Stradella A, Santos C, Laquente B, et al. Plasma neurofilament light chain levels in chemotherapy-induced peripheral neurotoxicity according to type of anticancer drug. Eur J Neurol. 2024. https:\/\/doi.org\/10.1111\/ene.16369.","journal-title":"Eur J Neurol"},{"key":"4053_CR31","unstructured":"Henningsson A SA, Loos WJ, Verweij J, Silvander M, Karlsson MO. Population Pharmacokinetic Model for Cremophor EL. PAGE. 2005;https:\/\/www.page-meeting.org\/?abstract=770. Accessed 01 May 2022"},{"issue":"12","key":"4053_CR32","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/psp4.12472","volume":"8","author":"Q Fu","year":"2019","unstructured":"Fu Q, Sun X, Lustburg MB, Sparreboom A, Hu S. Predicting paclitaxel disposition in humans with whole-body physiologically-based pharmacokinetic modeling. CPT Pharmacomet Syst Pharmacol. 2019;8(12):931\u20139.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"7","key":"4053_CR33","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1002\/jps.22073","volume":"99","author":"I Mahmood","year":"2010","unstructured":"Mahmood I. Theoretical versus empirical allometry: facts behind theories application to pharmacokinetics. J Pharm Sci. 2010;99(7):2927\u201333.","journal-title":"J Pharm Sci"},{"issue":"9","key":"4053_CR34","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1124\/dmd.107.015222","volume":"35","author":"M Frid\u00e9n","year":"2007","unstructured":"Frid\u00e9n M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos. 2007;35(9):1711\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"4053_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-3565(24)39296-1","volume":"293","author":"HJ Kuh","year":"2000","unstructured":"Kuh HJ, Jang SH, Wientjes MG, Au JL. Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther. 2000;293(3):761\u201370.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4053_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-022-00935-6","volume":"15","author":"K Sj\u00f6lin","year":"2022","unstructured":"Sj\u00f6lin K, Kultima K, Larsson A, Freyhult E, Zjukovskaja C, Alkass K, et al. Distribution of five clinically important neuroglial proteins in the human brain. Mol Brain. 2022;15(1): 52.","journal-title":"Mol Brain"},{"issue":"36","key":"4053_CR37","doi-asserted-by":"publisher","first-page":"11316","DOI":"10.1523\/JNEUROSCI.1942-09.2009","volume":"29","author":"A Yuan","year":"2009","unstructured":"Yuan A, Sasaki T, Rao MV, Kumar A, Kanumuri V, Dunlop DS, et al. Neurofilaments form a highly stable stationary cytoskeleton after reaching a critical level in axons. J Neurosci. 2009;29(36):11316\u201329.","journal-title":"J Neurosci"},{"issue":"11","key":"4053_CR38","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1093\/brain\/awad234","volume":"146","author":"S Keddie","year":"2023","unstructured":"Keddie S, Smyth D, Keh RYS, Chou MKL, Grant D, Surana S, et al. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain. 2023;146(11):4562\u201373.","journal-title":"Brain"},{"issue":"7","key":"4053_CR39","first-page":"1454","volume":"59","author":"A Sparreboom","year":"1999","unstructured":"Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated Alteration of Paclitaxel Distribution in Human Blood: Clinical Pharmacokinetic Implications. Can Res. 1999;59(7):1454\u20137.","journal-title":"Can Res"},{"issue":"11","key":"4053_CR40","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1073\/pnas.85.11.3762","volume":"85","author":"LM Greenberger","year":"1988","unstructured":"Greenberger LM, Lothstein L, Williams SS, Horwitz SB. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci U S A. 1988;85(11):3762\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4053_CR41","doi-asserted-by":"crossref","unstructured":"Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D, et al. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother. 2011;65(6):417\u201326.","DOI":"10.1016\/j.biopha.2011.04.031"},{"key":"4053_CR42","doi-asserted-by":"publisher","first-page":"113121","DOI":"10.1016\/j.expneurol.2019.113121","volume":"324","author":"NP Staff","year":"2020","unstructured":"Staff NP, Fehrenbacher JC, Caillaud M, Damaj MI, Segal RA, Rieger S. Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol. 2020;324:113121.","journal-title":"Exp Neurol"},{"issue":"13","key":"4053_CR43","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (Oxford, England\u202f: 1990). 2001;37(13):1590\u20138.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"3","key":"4053_CR44","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1007\/s11357-025-01561-5","volume":"47","author":"R Patai","year":"2025","unstructured":"Patai R, Kiss T, Gulej R, Nyul-Toth A, Csik B, Chandragiri SS, et al. Transcriptomic profiling of senescence effects on blood-brain barrier-related gene expression in brain capillary endothelial cells in a mouse model of paclitaxel-induced chemobrain. Geroscience. 2025;47(3):3677\u201391.","journal-title":"Geroscience"},{"issue":"25","key":"4053_CR45","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1523\/JNEUROSCI.1081-12.2012","volume":"32","author":"A Yuan","year":"2012","unstructured":"Yuan A, Sasaki T, Kumar A, Peterhoff CM, Rao MV, Liem RK, et al. Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J Neurosci. 2012;32(25):8501\u20138.","journal-title":"J Neurosci"},{"key":"4053_CR46","unstructured":"Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Academic Press; 2013."},{"issue":"4","key":"4053_CR47","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1152\/physrev.00027.2007","volume":"88","author":"E Sykov\u00e1","year":"2008","unstructured":"Sykov\u00e1 E, Nicholson C. Diffusion in brain extracellular space. Physiol Rev. 2008;88(4):1277\u2013340.","journal-title":"Physiol Rev"},{"issue":"5","key":"4053_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0166-2236(98)01261-2","volume":"21","author":"C Nicholson","year":"1998","unstructured":"Nicholson C, Sykov\u00e1 E. Extracellular space structure revealed by diffusion analysis. Trends Neurosci. 1998;21(5):207\u201315.","journal-title":"Trends Neurosci"},{"issue":"1","key":"4053_CR49","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0021-9258(19)52646-1","volume":"203","author":"RM Forbes","year":"1953","unstructured":"Forbes RM, Cooper AR, Mitchell HH. The composition of the adult human body as determined by chemical analysis. J Biol Chem. 1953;203(1):359\u201366.","journal-title":"J Biol Chem"},{"issue":"4","key":"4053_CR50","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/01.RES.4.4.419","volume":"4","author":"NB Everett","year":"1956","unstructured":"Everett NB, Simmons B, Lasher EP. Distribution of blood (Fe 59) and plasma (I 131) volumes of rats determined by liquid nitrogen freezing. Circ Res. 1956;4(4):419\u201324.","journal-title":"Circ Res"},{"key":"4053_CR51","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/0006-8993(73)90668-9","volume":"52","author":"NH Bass","year":"1973","unstructured":"Bass NH, Lundborg P. Postnatal development of bulk flow in the cerebrospinal fluid system of the albino rat: clearance of carboxyl-( 14 C)inulin after intrathecal infusion. Brain Res. 1973;52:323\u201332.","journal-title":"Brain Res"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04053-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04053-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04053-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:54:02Z","timestamp":1778867642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04053-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4053"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04053-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors of this work declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}